Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30245720,flow rate,Mobile phase consisting of acetonitrile (0.1% formic acid) and water (0.1% formic acid) was pumped in binary gradient mode at flow rate of 150 μL/min.,"Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),[μl] / [min],150,8842,DB00222,Glimepiride
,30245720,elution time,"Glibenclamide and IS elution time was about 1.0 min, and total run time was 2.0 min.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),min,1.0,8843,DB00222,Glimepiride
,30245720,total run time,"Glibenclamide and IS elution time was about 1.0 min, and total run time was 2.0 min.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),min,2.0,8844,DB00222,Glimepiride
,30245720,Accuracy,"Accuracy of the method at LQC, MQC, and HQC was 109.7% (± 6.7), 93.6% (± 0.4), and 99.3% (± 1.9), respectively.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),%,109.7,8845,DB00222,Glimepiride
,30245720,Accuracy,"Accuracy of the method at LQC, MQC, and HQC was 109.7% (± 6.7), 93.6% (± 0.4), and 99.3% (± 1.9), respectively.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),%,93.6,8846,DB00222,Glimepiride
,30245720,Accuracy,"Accuracy of the method at LQC, MQC, and HQC was 109.7% (± 6.7), 93.6% (± 0.4), and 99.3% (± 1.9), respectively.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),%,99.3,8847,DB00222,Glimepiride
,30245720,Recovery,"Recovery at LLQC, MQC, and HQC was 104.2% (± 4.9), 100.6% (± 0.9), and 102.9% (± 5.8), respectively.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),%,104.2,8848,DB00222,Glimepiride
,30245720,Recovery,"Recovery at LLQC, MQC, and HQC was 104.2% (± 4.9), 100.6% (± 0.9), and 102.9% (± 5.8), respectively.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),%,100.6,8849,DB00222,Glimepiride
,30245720,Recovery,"Recovery at LLQC, MQC, and HQC was 104.2% (± 4.9), 100.6% (± 0.9), and 102.9% (± 5.8), respectively.","Rapid, Validated UPLC-MS/MS Method for Determination of Glibenclamide in Rat Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30245720/),%,102.9,8850,DB00222,Glimepiride
,15358318,retention time,Glimepiride was eluted with retention time 34.9 min without interference of endogenous substance from plasma.,Determination of glimepiride in human plasma using semi-microbore high performance liquid chromatography with column-switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358318/),min,34.9,10648,DB00222,Glimepiride
,15358318,limit of quantification (LOQ),The limit of quantification (LOQ) was 10 ng/ml for glimepiride.,Determination of glimepiride in human plasma using semi-microbore high performance liquid chromatography with column-switching. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15358318/),[ng] / [ml],10,10649,DB00222,Glimepiride
,28069690,flow rate,The chromatographic analysis was performed on Waters-600 system using an isocratic mobile phase comprising methanol:water (80:20 % v/v) with pH of water modified to three using formic acid at a flow rate of 1.0 mL/min and Kinetex C18 column maintained at 30 ± 1°C.,Development of Solid-Phase Extraction and HPLC Method for Simultaneous Estimation of Ilaprazole and Glimepiride in Rat Plasma: Application to Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069690/),[ml] / [min],1.0,16318,DB00222,Glimepiride
,28069690,total run time,"IS, ILA and GLM eluted at 2.04, 4.7 and 7.4 min, respectively, and the total run time was 10 min.",Development of Solid-Phase Extraction and HPLC Method for Simultaneous Estimation of Ilaprazole and Glimepiride in Rat Plasma: Application to Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28069690/),min,10,16319,DB00222,Glimepiride
,32092631,extraction recovery,"The established method has good linearity (1-2000ng•mL-1), low quantification limit (1ng•mL-1), good precision (RSDs≤12 %), and satisfactory extraction recovery (71.20-85.70 %).",Magnetic solid phase extraction followed with LC-MS/MS for determination of glimepiride in beagle dog plasma and its application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32092631/),%,71.20-85.70,33566,DB00222,Glimepiride
,15651098,flow rate,"The chromatographic separation was performed on a reversed-phase Hypersil ODScolumn (250 x 4.6 mm i.d.; 5 microm particle size) using a mobile phase consisting of formic acid 0.05 M-acetonitrile (28:72, v/v), pumped at a flow rate of 0.3 ml min(-1) heated to 25 degrees C.",Improved liquid chromatographic tandem mass spectrometric determination and pharmacokinetic study of glimepiride in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15651098/),[ml] / [min],0.3,39216,DB00222,Glimepiride
,22587345,AUC(inf),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,95.0,39663,DB00222,Glimepiride
,22587345,AUC(inf),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,100.0,39664,DB00222,Glimepiride
,22587345,AUC(inf),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,99.1,39665,DB00222,Glimepiride
,22587345,C(max),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,96.5,39666,DB00222,Glimepiride
,22587345,C(max),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,93.5,39667,DB00222,Glimepiride
,22587345,C(max),"Similarly, multiple doses of sitagliptin, pioglitazone or glimepiride did not change the pharmacokinetics of a single dose of ipragliflozin (AUC(inf) : 95.0 [93.4-103.1], 100.0 [98.1-102.0], 99.1 [96.6-101.6]; and C(max) : 96.5 [90.4-103.1], 93.5 [86.3-101.2], 97.3 [89.2-106.2]).","No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22587345/),,97.3,39668,DB00222,Glimepiride
,16958825,maximal increase in insulin secretion,The maximal increase in insulin secretion was 9.98 mIU/L and the maximal decrease in plasma glucose was 19.33 mg/dL.,Pharmacokinetic and pharmacodynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958825/),[miu] / [l],9.98,48107,DB00222,Glimepiride
,32337660,time to peak plasma concentrations (Tmax),"Oral absorption was rapid, with time to peak plasma concentrations (Tmax) occurring at 1 h (fasted) and 2 h (fed) postdose.","Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,1,52327,DB00222,Glimepiride
,32337660,time to peak plasma concentrations (Tmax),"Oral absorption was rapid, with time to peak plasma concentrations (Tmax) occurring at 1 h (fasted) and 2 h (fed) postdose.","Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,2,52328,DB00222,Glimepiride
,32337660,terminal phase half-life,The terminal phase half-life ranged from 11 to 18 h and steady-state concentrations were achieved by 6 days after initiating once-daily dosing.,"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),h,11 to 18,52329,DB00222,Glimepiride
,32337660,absolute bioavailability,Ertugliflozin is categorized as a Biopharmaceutical Classification System Class I drug with an absolute bioavailability of ~ 100% under fasted conditions.,"Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337660/),%,100,52330,DB00222,Glimepiride
,16142016,AUC,Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).,Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142016/),[mg] / [l·min],758,58897,DB00222,Glimepiride
,16142016,AUC,Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).,Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142016/),[mg] / [l·min],780,58898,DB00222,Glimepiride
,16142016,AUC,Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).,Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142016/),[mu] / [l·min],2327,58899,DB00222,Glimepiride
,16142016,AUC,Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).,Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142016/),[mu] / [l·min],2148,58900,DB00222,Glimepiride
,30906140,peak serum concentration (C max),Glimepiride peak serum concentration (C max) was 126.01 ng/mL and was reached within 1 h (T max) of administration.,Development and Validation of Liquid Chromatography Method for Determination of Glimepiride in Presence of (Vimto®) Soft Drinks in Rats: Application to Pharmacokinetics Studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906140/),[ng] / [ml],126.01,59371,DB00222,Glimepiride
,30906140,T max,Glimepiride peak serum concentration (C max) was 126.01 ng/mL and was reached within 1 h (T max) of administration.,Development and Validation of Liquid Chromatography Method for Determination of Glimepiride in Presence of (Vimto®) Soft Drinks in Rats: Application to Pharmacokinetics Studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906140/),h,1,59372,DB00222,Glimepiride
,30906140,area under curve (AUC),Mean area under curve (AUC) was 964.70 ng/mL and was reached within 24 h of administration.,Development and Validation of Liquid Chromatography Method for Determination of Glimepiride in Presence of (Vimto®) Soft Drinks in Rats: Application to Pharmacokinetics Studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906140/),[ng] / [ml],964.70,59373,DB00222,Glimepiride
,30906140,peak serum concentration,The Vimto soft drink significantly (P < 0.050) reduced glimepiride peak serum concentration to 57.87 ng/mL and was reached within 2 h of administration.,Development and Validation of Liquid Chromatography Method for Determination of Glimepiride in Presence of (Vimto®) Soft Drinks in Rats: Application to Pharmacokinetics Studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906140/),[ng] / [ml],57.87,59374,DB00222,Glimepiride
,30906140,AUC,AUC was significantly reduced to 335.04 ng*h/mL (P < 0.050).,Development and Validation of Liquid Chromatography Method for Determination of Glimepiride in Presence of (Vimto®) Soft Drinks in Rats: Application to Pharmacokinetics Studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30906140/),[h·ng] / [ml],335.04,59375,DB00222,Glimepiride
,29403791,flow rate,The reconstituted samples were chromatographed on a Alltima HP C18 column by using a 60:40 (v/v) mixture of acetonitrile and 10 mM ammonium acetate (pH 3.0) as the mobile phase at a flow rate of 1.1 mL/min.,"Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403791/),[ml] / [min],1.1,74796,DB00222,Glimepiride
,29403791,run time,A run time of 2.5 min for each sample made it possible to analyze more than 300 plasma samples per day.,"Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403791/),min,2.5,74797,DB00222,Glimepiride
,27240565,flow rate,"Chromatographic separation was achieved on a Waters ACQUITY UPLC BEH C18 column (2.1 mm × 100 mm, 1.7 μm particle size, Waters Corp., Milford, MA, USA) and inline 0.2 μm stainless steel frit filter (Waters Corp.) with acetonitrile-0.1% formic acid as the mobile phase at a flow rate of 0.4 mL/min with gradient elution.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),[ml] / [min],0.4,87834,DB00222,Glimepiride
,27240565,retention times,"The retention times were ∼3.29 min for BOS, 3.56 min for GLP, 1.42 min for HYBOS, 1.53 min for M1 and 3.22 min for IS.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),min,∼3.29,87835,DB00222,Glimepiride
,27240565,retention times,"The retention times were ∼3.29 min for BOS, 3.56 min for GLP, 1.42 min for HYBOS, 1.53 min for M1 and 3.22 min for IS.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),min,3.56,87836,DB00222,Glimepiride
,27240565,retention times,"The retention times were ∼3.29 min for BOS, 3.56 min for GLP, 1.42 min for HYBOS, 1.53 min for M1 and 3.22 min for IS.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),min,1.42,87837,DB00222,Glimepiride
,27240565,retention times,"The retention times were ∼3.29 min for BOS, 3.56 min for GLP, 1.42 min for HYBOS, 1.53 min for M1 and 3.22 min for IS.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),min,1.53,87838,DB00222,Glimepiride
,27240565,retention times,"The retention times were ∼3.29 min for BOS, 3.56 min for GLP, 1.42 min for HYBOS, 1.53 min for M1 and 3.22 min for IS.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),min,3.22,87839,DB00222,Glimepiride
exceeded,27240565,recoveries,"The mean recoveries of BOS, GLP, HYBOS, M1 and ambrisentan from the plasma exceeded 90.4%.","Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27240565/),%,90.4,87840,DB00222,Glimepiride
,24835512,flow rate,"Liquid-liquid extraction was carried out on 0.2 mL of human plasma using ethyl acetate, and chromatographic separation was performed on an Agilent Eclipse plus C18 column (4.6 mm × 100 mm, 3.5 μm) using a mobile phase consisting of methanol-water-formic acid (95:5:0.1, v/v/v, plus 5mM ammonium acetate) at a flow rate of 0.8 mL/min.",Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24835512/),[ml] / [min],0.8,94507,DB00222,Glimepiride
,24835512,total run time,The total run time was 3.0 min and the elution time was about 2.4 min.,Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24835512/),min,3.0,94508,DB00222,Glimepiride
,24835512,elution time,The total run time was 3.0 min and the elution time was about 2.4 min.,Simultaneous determination of glimepiride and pioglitazone in human plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24835512/),min,2.4,94509,DB00222,Glimepiride
,15563069,relative bioavailability,The relative bioavailability of glimepiride-TDDS was 20.3% versus oral administration.,[Preparation and evaluation in vivo and in vitro of glimepiride gel-matrix controlled-release patch]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563069/),%,20.3,101669,DB00222,Glimepiride
,31760750,IC50,"The present study showed that drugs such as probenecid and glimepiride displayed potent inhibition toward the OAT3-mediated SVAG transport, with IC50 values of 4.9 and 0.8 μM, respectively.","Interaction of Organic Anion Transporter 3-Mediated Uptake of Steviol Acyl Glucuronide, a Major Metabolite of Rebaudioside A, with Selected Drugs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31760750/),μM,4.9,101951,DB00222,Glimepiride
,31760750,IC50,"The present study showed that drugs such as probenecid and glimepiride displayed potent inhibition toward the OAT3-mediated SVAG transport, with IC50 values of 4.9 and 0.8 μM, respectively.","Interaction of Organic Anion Transporter 3-Mediated Uptake of Steviol Acyl Glucuronide, a Major Metabolite of Rebaudioside A, with Selected Drugs. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31760750/),μM,0.8,101952,DB00222,Glimepiride
,22291058,flow rate,"The analyte and glimepiride d8 (internal standard, IS) are chromatographed on a C(18) column; the mobile phase is acetonitrile-2 mm ammonium formate (88:12, v/v), with the pH adjusted to 3.5 with formic acid, at a flow rate of 0.5 mL/min.",Rapid and specific approach for direct measurement of glimepiride in human plasma by LC-ESI-MS-MS employing automated 96 well format: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22291058/),[ml] / [min],0.5,103358,DB00222,Glimepiride
,22291058,retention times,"The retention times of glimepiride and the IS are 0.93 min, and the runtime is 1.6 min per sample.",Rapid and specific approach for direct measurement of glimepiride in human plasma by LC-ESI-MS-MS employing automated 96 well format: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22291058/),min,0.93,103359,DB00222,Glimepiride
,22291058,runtime,"The retention times of glimepiride and the IS are 0.93 min, and the runtime is 1.6 min per sample.",Rapid and specific approach for direct measurement of glimepiride in human plasma by LC-ESI-MS-MS employing automated 96 well format: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22291058/),[min] / [sample],1.6,103360,DB00222,Glimepiride
,22291058,m/z,"Selected reaction monitoring of MH(+) at m/z 491.20 and 499.26 result in stable fragment ions with m/z 351.80 and 359.96 for glimepiride and the IS, respectively.",Rapid and specific approach for direct measurement of glimepiride in human plasma by LC-ESI-MS-MS employing automated 96 well format: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22291058/),,351.80,103361,DB00222,Glimepiride
,22291058,m/z,"Selected reaction monitoring of MH(+) at m/z 491.20 and 499.26 result in stable fragment ions with m/z 351.80 and 359.96 for glimepiride and the IS, respectively.",Rapid and specific approach for direct measurement of glimepiride in human plasma by LC-ESI-MS-MS employing automated 96 well format: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22291058/),,359.96,103362,DB00222,Glimepiride
,22291058,recovery,The recovery of glimepiride and the IS ranged from 81.91 to 83.36%.,Rapid and specific approach for direct measurement of glimepiride in human plasma by LC-ESI-MS-MS employing automated 96 well format: application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22291058/),%,81.91 to 83.36,103363,DB00222,Glimepiride
,23884662,flow rate,Chromatographic separation was achieved on C18 column using methanol: water (85:15 v/v) as mobile phase at a flow rate of 1 ml/min and UV detection at 230 nm.,Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884662/),[ml] / [min],1,110935,DB00222,Glimepiride
,23884662,retention time,The retention time of GLIM and SIL was found to be 2.5 and 4.0 min respectively with total run time of 7 min.,Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884662/),min,2.5,110936,DB00222,Glimepiride
,23884662,retention time,The retention time of GLIM and SIL was found to be 2.5 and 4.0 min respectively with total run time of 7 min.,Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884662/),min,4.0,110937,DB00222,Glimepiride
,23884662,total run time,The retention time of GLIM and SIL was found to be 2.5 and 4.0 min respectively with total run time of 7 min.,Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884662/),min,7,110938,DB00222,Glimepiride
,31496686,polydispersity index (PDI),"Minimum particle size and polydispersity index (PDI) values were found to be 152.4±2.42 nm and 0.23±0.01, respectively, using hydroxypropyl methylcellulose: 6 cPs, 1% w/v, polyvinylpyrrolidone K30 1% w/v, and sodium lauryl sulfate 0.12% w/v, keeping ultrasonication power input at 400 W, with 15 minutes' processing at 3-second pauses.",Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31496686/),,0.23,113024,DB00222,Glimepiride
,28159531,flow rate,"Waters XTerra RP HPLC column (4.6×100mm, 5μm) with mobile phase consisting of acetonitrile and 10mM ammonium acetate (pH-6.0) in the ratio 85:15 (v/v) at a flow rate of 1mL/min was used for the chromatographic separation.",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),[ml] / [min],1,113708,DB00222,Glimepiride
,28159531,m/,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,420.17,113709,DB00222,Glimepiride
,28159531,m/z,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,489.59,113710,DB00222,Glimepiride
,28159531,m/z,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,350.12,113711,DB00222,Glimepiride
,28159531,m/z,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,380.08,113712,DB00222,Glimepiride
,28159531,m/z,"The negative ionization mode with MRM transitions: m/z 420.17→288.13 for PIT, m/z 489.59→350.12 for GLI and m/z 380.08→316.31for celecoxib as internal standard (IS).",A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),,316.31,113713,DB00222,Glimepiride
,28159531,total run time,A total run time of 3min and LLOQ was found to be 5ng/mL for both PIT and GLI.,A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),min,3,113714,DB00222,Glimepiride
,28159531,total run time,A total run time of 3min and LLOQ was found to be 5ng/mL for both PIT and GLI.,A validated LC-MS/MS method for the estimation of glimepiride and pitavastatin in rat plasma: Application to drug interaction studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28159531/),[ng] / [ml],5,113715,DB00222,Glimepiride
,25316572,urinary excretion,"Although urinary excretion of ipragliflozin is low (approximately 1 %), tubular concentration of free ipragliflozin is adequate to provide pharmacological activities.",Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25316572/),%,1,120234,DB00222,Glimepiride
,34313291,flow rate,"Chromatographic separation was performed on a C18 (2.1 × 50 mm, 2.7 μm, Agilent) column with isocratic elution using water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid at a flow rate of 0.4 mL/min.",A Sensitive HPLC-MS/MS Method for Determination of Obeticholic Acid in Human Plasma: Application to a Pharmacokinetic Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34313291/),[ml] / [min],0.4,124572,DB00222,Glimepiride
,34313291,m/,The precursor-product ion pairs for MRM were m/z 465.3 → 419.3 for obeticholic acid and m/z 489.3 → 224.8 for the IS.,A Sensitive HPLC-MS/MS Method for Determination of Obeticholic Acid in Human Plasma: Application to a Pharmacokinetic Study in Healthy Volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34313291/),,465.3,124573,DB00222,Glimepiride
,2361988,detection limit,The detection limit was 5 ng/ml for glimepiride and metabolite II and 10 ng/ml for metabolite I using 1 ml of serum.,Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2361988/),[ng] / [ml],5,124692,DB00222,Glimepiride
,2361988,detection limit,The detection limit was 5 ng/ml for glimepiride and metabolite II and 10 ng/ml for metabolite I using 1 ml of serum.,Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-column derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2361988/),[ng] / [ml],10,124693,DB00222,Glimepiride
,11309547,elimination half-life,The mean elimination half-life of glimepiride was prolonged from 2.0 to 3.3 hours (P <.0001) by fluconazole.,Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309547/),h,2.0,125945,DB00222,Glimepiride
,11309547,elimination half-life,The mean elimination half-life of glimepiride was prolonged from 2.0 to 3.3 hours (P <.0001) by fluconazole.,Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309547/),h,3,125946,DB00222,Glimepiride
,11309547,elimination half-life,"However, the mean peak plasma concentration of glimepiride was 143% (P <.05) of the control and the elimination half-life was prolonged from 2.0 to 2.3 hours (P <.01) by fluvoxamine.",Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309547/),h,2.0,125947,DB00222,Glimepiride
,11309547,elimination half-life,"However, the mean peak plasma concentration of glimepiride was 143% (P <.05) of the control and the elimination half-life was prolonged from 2.0 to 2.3 hours (P <.01) by fluvoxamine.",Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11309547/),h,2.3,125948,DB00222,Glimepiride
,22744744,retention times,"The retention times of galantamine and IS are 1.1 and 0.71 min, which showsthe high throughput potential of the proposed method.",Quantification of galantamine in human plasma by validated liquid chromatography-tandem mass spectrometry using glimepride as an internal standard: application to bioavailability studies in 32 healthy Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22744744/),min,1.1,132082,DB00222,Glimepiride
,22744744,retention times,"The retention times of galantamine and IS are 1.1 and 0.71 min, which showsthe high throughput potential of the proposed method.",Quantification of galantamine in human plasma by validated liquid chromatography-tandem mass spectrometry using glimepride as an internal standard: application to bioavailability studies in 32 healthy Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22744744/),min,0.71,132083,DB00222,Glimepiride
,22257580,time to reach maximum concentration,The SR formulation showed a delay in the time to reach maximum concentration for metformin from 1.0 - 4.0 h to 4.0 - 8.0 h and a decreased AUC24 value; the geometric mean ratio for metformin AUC24 was 0.87 (0.74 - 1.03) for Treatment relative to Reference 1 and 0.75 (0.63 - 0.88) for Treatment relative to Reference 2.,Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22257580/),h,1.0 - 4.0,140503,DB00222,Glimepiride
,22257580,time to reach maximum concentration,The SR formulation showed a delay in the time to reach maximum concentration for metformin from 1.0 - 4.0 h to 4.0 - 8.0 h and a decreased AUC24 value; the geometric mean ratio for metformin AUC24 was 0.87 (0.74 - 1.03) for Treatment relative to Reference 1 and 0.75 (0.63 - 0.88) for Treatment relative to Reference 2.,Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22257580/),h,4.0 - 8.0,140504,DB00222,Glimepiride
,12369756,urinary recovery,Mean urinary recovery of M1 plus M2 was 50% of the dose for the glimepiride tablet and 51% for the intravenous injection.,Absolute bioavailability of glimepiride (Amaryl) after oral administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369756/),%,50,141724,DB00222,Glimepiride
,12369756,urinary recovery,Mean urinary recovery of M1 plus M2 was 50% of the dose for the glimepiride tablet and 51% for the intravenous injection.,Absolute bioavailability of glimepiride (Amaryl) after oral administration. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369756/),%,51,141725,DB00222,Glimepiride
,12369756,absolute bioavailability,"The absolute bioavailability of the tablet formulation was 107% (AUDC(glimepiride)), 109% (AUDC(M1)) and 97% (urinary recovery).",Absolute bioavailability of glimepiride (Amaryl) after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369756/),%,107,141726,DB00222,Glimepiride
,12369756,absolute bioavailability,"The absolute bioavailability of the tablet formulation was 107% (AUDC(glimepiride)), 109% (AUDC(M1)) and 97% (urinary recovery).",Absolute bioavailability of glimepiride (Amaryl) after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369756/),%,109,141727,DB00222,Glimepiride
,12369756,absolute bioavailability,"The absolute bioavailability of the tablet formulation was 107% (AUDC(glimepiride)), 109% (AUDC(M1)) and 97% (urinary recovery).",Absolute bioavailability of glimepiride (Amaryl) after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12369756/),%,97,141728,DB00222,Glimepiride
,20110017,T(max),"After administration of the test and reference formulations, glimepiride was rapidly absorbed, reaching C(max) with a median T(max) of 1.75 and 2.0 hours, respectively, and then declined exponentially with an average t(1/2) of 8.2 and 8.5 hours.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),h,1.75,158946,DB00222,Glimepiride
,20110017,T(max),"After administration of the test and reference formulations, glimepiride was rapidly absorbed, reaching C(max) with a median T(max) of 1.75 and 2.0 hours, respectively, and then declined exponentially with an average t(1/2) of 8.2 and 8.5 hours.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),h,2.0,158947,DB00222,Glimepiride
,20110017,t(1/2),"After administration of the test and reference formulations, glimepiride was rapidly absorbed, reaching C(max) with a median T(max) of 1.75 and 2.0 hours, respectively, and then declined exponentially with an average t(1/2) of 8.2 and 8.5 hours.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),h,8.2,158948,DB00222,Glimepiride
,20110017,t(1/2),"After administration of the test and reference formulations, glimepiride was rapidly absorbed, reaching C(max) with a median T(max) of 1.75 and 2.0 hours, respectively, and then declined exponentially with an average t(1/2) of 8.2 and 8.5 hours.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),h,8.5,158949,DB00222,Glimepiride
,20110017,dose-normalized Cmax,"The mean (SD) dose-normalized Cmax values of glimepiride 1 and 2 mg were 168.2 (54.9) and 149.9 (47.4) ng/mL/mg, respectively; the mean dose-normalized AUC(last) values of glimepiride 1 and 2 mg were 681.5 (190.3) and 635.8 (194.1) ng x h/mL/mg.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),[ng] / [mg·ml],168.2,158950,DB00222,Glimepiride
,20110017,dose-normalized Cmax,"The mean (SD) dose-normalized Cmax values of glimepiride 1 and 2 mg were 168.2 (54.9) and 149.9 (47.4) ng/mL/mg, respectively; the mean dose-normalized AUC(last) values of glimepiride 1 and 2 mg were 681.5 (190.3) and 635.8 (194.1) ng x h/mL/mg.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),[ng] / [mg·ml],149.9,158951,DB00222,Glimepiride
,20110017,dose-normalized AUC(last),"The mean (SD) dose-normalized Cmax values of glimepiride 1 and 2 mg were 168.2 (54.9) and 149.9 (47.4) ng/mL/mg, respectively; the mean dose-normalized AUC(last) values of glimepiride 1 and 2 mg were 681.5 (190.3) and 635.8 (194.1) ng x h/mL/mg.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),[h·ng] / [mg·ml],681.5,158952,DB00222,Glimepiride
,20110017,dose-normalized AUC(last),"The mean (SD) dose-normalized Cmax values of glimepiride 1 and 2 mg were 168.2 (54.9) and 149.9 (47.4) ng/mL/mg, respectively; the mean dose-normalized AUC(last) values of glimepiride 1 and 2 mg were 681.5 (190.3) and 635.8 (194.1) ng x h/mL/mg.","Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20110017/),[h·ng] / [mg·ml],635.8,158953,DB00222,Glimepiride
,21355443,extraction recovery,"The mean extraction recovery was found to be 90.2 +/- 4.5, 76.8 +/- 2.8 and 85.2 +/- 5.2% for PIO, GLM and internal standard, respectively.",Novel liquid chromatographic method for simultaneous estimation of pioglitazone and glimepiride in rat plasma by solid phase extraction: application to preclinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355443/),%,90.2,172432,DB00222,Glimepiride
,21355443,extraction recovery,"The mean extraction recovery was found to be 90.2 +/- 4.5, 76.8 +/- 2.8 and 85.2 +/- 5.2% for PIO, GLM and internal standard, respectively.",Novel liquid chromatographic method for simultaneous estimation of pioglitazone and glimepiride in rat plasma by solid phase extraction: application to preclinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355443/),%,76.8,172433,DB00222,Glimepiride
,21355443,extraction recovery,"The mean extraction recovery was found to be 90.2 +/- 4.5, 76.8 +/- 2.8 and 85.2 +/- 5.2% for PIO, GLM and internal standard, respectively.",Novel liquid chromatographic method for simultaneous estimation of pioglitazone and glimepiride in rat plasma by solid phase extraction: application to preclinical pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355443/),%,85.2,172434,DB00222,Glimepiride
,31094010,"steady-state Cmax,ss","The steady-state Cmax,ss values of teneligliptin without and with glimepiride were 207.01 ng/mL and 202.15 ng/mL, respectively.",Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094010/),[ng] / [ml],207.01,178351,DB00222,Glimepiride
,31094010,"steady-state Cmax,ss","The steady-state Cmax,ss values of teneligliptin without and with glimepiride were 207.01 ng/mL and 202.15 ng/mL, respectively.",Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094010/),[ng] / [ml],202.15,178352,DB00222,Glimepiride
,31094010,AUCτ,"Its AUCτ values at steady-state without and with glimepiride were 1527.8 ng · h/mL and 1578.6 ng · h/mL, respectively.",Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094010/),[h·ng] / [ml],1527.8,178353,DB00222,Glimepiride
,31094010,AUCτ,"Its AUCτ values at steady-state without and with glimepiride were 1527.8 ng · h/mL and 1578.6 ng · h/mL, respectively.",Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094010/),[h·ng] / [ml],1578.6,178354,DB00222,Glimepiride
,8960852,relative total clearance,"Mean relative total clearance and mean volume of distribution of both single (41.6 ml/ min and 8.47 litres, respectively, when creatinine clearance was above 50 ml/min) and multiple doses of glimepiride increased in proportion to the degree of renal impairment (to 91.1 ml/min and 14.98 litres, respectively, when creatinine clearance was below 20 ml/min, single dose), whereas the terminal halflife and mean time remained unchanged.",Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8960852/),[ml] / [min],41.6,182241,DB00222,Glimepiride
,8960852,relative total clearance,"Mean relative total clearance and mean volume of distribution of both single (41.6 ml/ min and 8.47 litres, respectively, when creatinine clearance was above 50 ml/min) and multiple doses of glimepiride increased in proportion to the degree of renal impairment (to 91.1 ml/min and 14.98 litres, respectively, when creatinine clearance was below 20 ml/min, single dose), whereas the terminal halflife and mean time remained unchanged.",Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8960852/),[ml] / [min],91.1,182242,DB00222,Glimepiride
,8960852,volume of distribution,"Mean relative total clearance and mean volume of distribution of both single (41.6 ml/ min and 8.47 litres, respectively, when creatinine clearance was above 50 ml/min) and multiple doses of glimepiride increased in proportion to the degree of renal impairment (to 91.1 ml/min and 14.98 litres, respectively, when creatinine clearance was below 20 ml/min, single dose), whereas the terminal halflife and mean time remained unchanged.",Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8960852/),l,8.47,182243,DB00222,Glimepiride
,8960852,volume of distribution,"Mean relative total clearance and mean volume of distribution of both single (41.6 ml/ min and 8.47 litres, respectively, when creatinine clearance was above 50 ml/min) and multiple doses of glimepiride increased in proportion to the degree of renal impairment (to 91.1 ml/min and 14.98 litres, respectively, when creatinine clearance was below 20 ml/min, single dose), whereas the terminal halflife and mean time remained unchanged.",Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8960852/),l,14.98,182244,DB00222,Glimepiride
,28831818,drug plasma concentration,"The volunteer group administered the optimized GLMP tablet exhibited higher drug plasma concentration (147.4 ng/mL), longer time to reach maximum plasma concentration (4 h) and longer t1/2 (7.236 h) compared to other groups.",Clinical pharmacokinetic study for the effect of glimepiride matrix tablets developed by quality by design concept. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28831818/),[ng] / [ml],147.4,195851,DB00222,Glimepiride
,28831818,time to reach maximum plasma concentration,"The volunteer group administered the optimized GLMP tablet exhibited higher drug plasma concentration (147.4 ng/mL), longer time to reach maximum plasma concentration (4 h) and longer t1/2 (7.236 h) compared to other groups.",Clinical pharmacokinetic study for the effect of glimepiride matrix tablets developed by quality by design concept. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28831818/),h,4,195852,DB00222,Glimepiride
,28831818,t1/2,"The volunteer group administered the optimized GLMP tablet exhibited higher drug plasma concentration (147.4 ng/mL), longer time to reach maximum plasma concentration (4 h) and longer t1/2 (7.236 h) compared to other groups.",Clinical pharmacokinetic study for the effect of glimepiride matrix tablets developed by quality by design concept. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28831818/),h,7.236,195853,DB00222,Glimepiride
,24702435,flux,"The optimized formulations showed flux value of (2.88 and 4.428 μg/cm(2)/h) through rat skin for chitosan and HPMC films, respectively.",Optimization of self-nanoemulsifying systems for the enhancement of in vivo hypoglycemic efficacy of glimepiride transdermal patches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702435/),[μg] / [cm(2)·h],2.88,204002,DB00222,Glimepiride
,24702435,flux,"The optimized formulations showed flux value of (2.88 and 4.428 μg/cm(2)/h) through rat skin for chitosan and HPMC films, respectively.",Optimization of self-nanoemulsifying systems for the enhancement of in vivo hypoglycemic efficacy of glimepiride transdermal patches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24702435/),[μg] / [cm(2)·h],4.428,204003,DB00222,Glimepiride
up to,27540291,solubility,"The optimized GMME was composed of Capryol 90 (oil), Cremophor RH40 (surfactant), and Transcutol (cosurfactant), and increased GM solubility up to 544.6±4.91 µg/mL.",Improved oral bioavailability of poorly water-soluble glimepiride by utilizing microemulsion technique. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27540291/),[μg] / [ml],544.6,216332,DB00222,Glimepiride
,27540291,polydispersity index,"The particle size and its polydispersity index were 38.9±17.46 nm and 0.266±0.057, respectively.",Improved oral bioavailability of poorly water-soluble glimepiride by utilizing microemulsion technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27540291/),,0.266,216333,DB00222,Glimepiride
,11719730,elimination half-life,The mean elimination half-life of glimepiride was prolonged from 2.1 to 2.3 hours (P <.05) by gemfibrozil.,Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719730/),h,2.1,220867,DB00222,Glimepiride
,11719730,elimination half-life,The mean elimination half-life of glimepiride was prolonged from 2.1 to 2.3 hours (P <.05) by gemfibrozil.,Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719730/),h,2.3,220868,DB00222,Glimepiride
,25736727,retention times,"The retention times of curdione and IS were 6.55 and 6.59 min, respectively.",Development and application of an analytical method for curdione quantification in pregnant Sprague-Dawley rats by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25736727/),min,6.55,242700,DB00222,Glimepiride
,25736727,retention times,"The retention times of curdione and IS were 6.55 and 6.59 min, respectively.",Development and application of an analytical method for curdione quantification in pregnant Sprague-Dawley rats by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25736727/),min,6.59,242701,DB00222,Glimepiride
,25736727,recovery,The mean recovery of curdione in rat plasma was 95.5-101.1%.,Development and application of an analytical method for curdione quantification in pregnant Sprague-Dawley rats by LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25736727/),%,95.5-101.1,242702,DB00222,Glimepiride
,28167473,plasma concentration,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),,0.16069,271090,DB00222,Glimepiride
,28167473,plasma concentration,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),,0.3227,271091,DB00222,Glimepiride
,28167473,urine concentration,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),[μg] / [ml],1.5994,271092,DB00222,Glimepiride
,28167473,urine concentration,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),[μg] / [ml],0.8665,271093,DB00222,Glimepiride
,28167473,renal clearance,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),m,1.224,271094,DB00222,Glimepiride
,28167473,renal clearance,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),m,1.550,271095,DB00222,Glimepiride
,28167473,renal clearance,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),,0.2064,271096,DB00222,Glimepiride
,28167473,renal clearance,"Mean (±SE) values for blood pH 7.445±0.05 and 7.382±0.05, urine pH 4.972±0.08 and 5.08±0.10, diuresis 0.0207±0.00 and 0.0237±0.00ml/min/kg, endogenous creatinine in plasma 9.048±0.33 and 8.613±0.024µg/ml, endogenous creatinine in urine 512.34±18.20 and 556.72±4.60µg/ml, Glimepiride plasma concentration 0.16069±0.00 and 0.3227±0.01µg/ml, Glimepiride urine concentration 1.5994±0.03 and 0.8665±0.04µg/ml, renal clearance of creatinine 1.224±0.09 and 1.550±0.09ml/min/kg, renal clearance of Glimepiride 0.2064±0.01 and 0.0641±0.00ml/min/kg and clearance ratio 0.1791±0.01 and 0.0414±0.00 were observed for Glimepiride alone and its concurrent administration with atorvastatin, respectively.",Therapeutic effect of atorvastatin on kidney functions and urinary excretion of Glimepiride in healthy adult human male subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28167473/),,0.0641,271097,DB00222,Glimepiride
,33136434,drug loading,GLM-GSN showed excellent drug loading (39.7% ± 0.7%) and sustained GLM release.,Development and Characterization of a Glimepiride-Loaded Gelatin-Coated Mesoporous Hollow Silica Nanoparticle Formulation and Evaluation of Its Hypoglycemic Effect on Type-2 Diabetes Model Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33136434/),%,39.7,272896,DB00222,Glimepiride
